Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease - Trial NCT06388863
Access comprehensive clinical trial information for NCT06388863 through Pure Global AI's free database. This phase not specified trial is sponsored by Shanghai Zhongshan Hospital and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 76 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Zhongshan Hospital
Timeline & Enrollment
N/A
Jun 01, 2024
May 31, 2026
Primary Outcome
Response rate of constipation in Parkinson's Disease (PD)
Summary
Participants will be allocated to FMT group or placebo group at a 1:1 ratio. For
 interventional group, patients will be given six FMT capsules twice a week for 24 weeks.
 Placebo capsules are identical in appearance and smell but contain milk powder. At each
 follow-up visits, participants complete specific scales to assess improvement in
 constipation, emotion and quality of life. Besides, fecal samples are collected for
 metagenomics and metabolomics sequencing and blood samples are tested peripheral
 concentration of levodopa.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06388863
Non-Device Trial